Newsstand | Page 18 | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

The Challenging World of Cytopenias: Distinguishing Myelodysplastic Syndromes From Other Disorders of Marrow Failure.

Originally Published: 07/31/2014
Research Review: Low blood counts can be attributed to several different medical conditions.  Distinguishing myelodysplastic syndromes (MDS) from other bone marrow failure disorders can be challenging; however, it is important in the determination of prognosis and treatment.  The use of molecular markers has become increasingly useful in making this distinction. Key-Findings: After benign causes of low blood counts, such as vitamin deficiencies, are excluded, the first step in a suspected bone marrow failure disorder is to examine the peripheral blood smear and perform a bone marrow...

Myelodysplastic Syndromes and autoimmune disorders: Cause or consequence?

Originally Published: 06/12/2014
This article reviews Myelodysplastic Syndromes (MDS) and the association with autoimmune disorders (AD). AD are frequently found in MDS patients, ranging from 10-30%. Patients generally are diagnosed with MDS around the time of symptomatic AD. Those patients with AD have a higher risk to develop MDS or acute myeloid leukemia (AML) than the general population – diseases including rheumatoid arthritis, Sjogren syndrome, lupus, seronegative arthritis, panarteritis nodosa, autoimmune hemolysis, and pernicious anemia. Those with both MDS and AD display clinical manifestations of AD 10-30% of the...

Clofarabine in the treatment of myelodysplastic syndromes

Originally Published: 02/27/2014
Clofarabine is a potential treatment option for patients with myelodysplastic syndromes (MDS) and is well tolerated in an older patient population.  It was previously approved in 2004 for children with acute lymphocytic leukemia (ALL) who failed at least two prior treatment regimens.  It acts as an inhibitor of DNA synthesis and can reduce the percentage of leukemic blasts in adult patients with MDS and acute myeloid leukemia (AML).  Early research studies identified 40 mg/m2 daily for 5 days per course as the standard dosing regimen. Key-Findings: In a study using single-agent clofarabine...

Clonal Evolution in Aplastic Anemia is Driven by Chromosomal Instability Rather than Mutations in Myeloid Malignancy Candidate Gene

Originally Published: 02/10/2014
Note: This review is based upon a presentation at the 2013 American Society of Hematology (ASH) Annual Meeting, December 7-10 in New Orleans, Louisiana.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract # 802 Bogdan Dumitriu, M.D., Xingmin Feng, Ph.D., Yasutaka Ueda, M.D., Ph.D., Sachiko Kajigaya, Ph.D., Danielle Townsley, M.D., Jun Zsu, Ph.D., Yoshi Wakabayashi, Ph.D., Yanqin Yang, M.S., Delong Liu, Ph.D., and Neal S. Young, M.D. Some patients with...

Current Outcome of HLA Identical Sibling vs Unrelated Donor Transplants in Severe Aplastic Anemia: An EBMT Analysis

Originally Published: 02/10/2014
Note: This review is based upon a presentation at the 2013 American Society of Hematology (ASH) Annual Meeting, December 7-10 in New Orleans, Louisiana.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract # 707 Andrea Bacigalupo, M.D., Gérard Socié, M.D., Ph.D., Rose-Marie Hamljadi, Mahmoud Aljurf, A. Mashan, Slawomira Kyrcz-Krzemien, M.D., A. Cybicka, H. Sengeloev, Ali Unal, M.D., Dietrich Beelen, M.D., A Locasciulli, Carlo Dufour, M.D., Jakob R. Passweg...

Spectrum of Genetic Alterations in Acquired Aplastic Anemia

Originally Published: 02/10/2014
Note: This review is based upon a presentation at the 2013 American Society of Hematology (ASH) Annual Meeting, December 7-10 in New Orleans, Louisiana.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract # 2464 Tetsuichi Yoshizato, M.D., Bogdan Dumitriu, M.D., Kohei Hosokawa, M.D., Ph.D., Hideki Makishima, M.D., Ph.D., Kenichi Yoshida, M.D., Yusuke Okuno, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Ph.D., Yasunobu Nagata, M.D., Takamasa Katagiri, Ph.D...

Spectrum of Genetic Alterations in Acquired Aplastic Anemia

Originally Published: 02/10/2014
Note: This review is based upon a presentation at the 2013 American Society of Hematology (ASH) Annual Meeting, December 7-10 in New Orleans, Louisiana.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract # 2464 Tetsuichi Yoshizato, M.D., Bogdan Dumitriu, M.D., Kohei Hosokawa, M.D., Ph.D., Hideki Makishima, M.D., Ph.D., Kenichi Yoshida, M.D., Yusuke Okuno, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Ph.D., Yasunobu Nagata, M.D., Takamasa Katagiri, Ph.D...

Complement Blockade with a C1 Esterase Inhibitor in Paroxysmal Nocturnal Hemoglobinuria

Originally Published: 01/31/2014
Note: This review is based upon a presentation at the 2013 American Society of Hematology (ASH) Annual Meeting, December 7-10 in New Orleans, Louisiana.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract # 594 Amy E. DeZern, M.D., M.H.S., Marc Uknis, M.D., Ph.D., Galina Mukhina, M.D., Ph.D., Jo Anne Saye, Ph.D., Jeffrey J. Pu, M.D., Ph.D., and Robert Brodsky, M.D. Patients with paroxysmal nocturnal hemoglobinuria (PNH) don’t have two important proteins,...

Insights into the Natural History of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis of the Presenting Clinical, Haematological and Flow Cytometric Features of 705 Patients Leads to Improved Classification and Prediction of Clinical Course

Originally Published: 01/31/2014
Note: This review is based upon a presentation at the 2013 American Society of Hematology (ASH) Annual Meeting, December 7-10 in New Orleans, Louisiana.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract # 3718 Stephen John Richards, Ph.D., Richard Kelly, M.D., Anita Hill, M.B.Ch.B., Ph.D., Anita Dickinson, M.Sc., Fiona Cullen, M.Sc., Jane Shingles, Ph.D., Matthew Cullen, M.Sc., and Peter Hillmen, M.B.Ch.B., Ph.D. A group of researchers from Great...

Clinical mutations associated with MDS and their importance for disease outcome

Originally Published: 11/22/2013
Myelodysplastic syndrome (MDS) is not one disease, but represents a group of diseases.  Each group has distinct clinical and pathological abnormalities.  Some groups are associated with a specific genetic abnormality, others with a mixture of genetic abnormalities.  It is important to understand the significance of the individual abnormalities, because it may help doctors to design a better patient-specific treatment plan or develop entirely new drugs based on what we know about a specific mutation in a specific gene. This study analyzed samples from 738 patients: 603 with MDS and 135 with...